Osteoimmunology and osteoporosis

Piet Geusens*1,2 and Willem F Lems3

Abstract
The concept of osteoimmunology is based on growing insight into the links between the immune system and bone at the anatomical, vascular, cellular, and molecular levels. In both rheumatoid arthritis (RA) and ankylosing spondylitis (AS), bone is a target of inflammation. Activated immune cells at sites of inflammation produce a wide spectrum of cytokines in favor of increased bone resorption in RA and AS, resulting in bone erosions, osteitis, and peri-inflammatory and systemic bone loss. Peri-inflammatory bone formation is impaired in RA, resulting in non-healing of erosions, and this allows a local vicious circle of inflammation between synovitis, osteitis, and local bone loss. In contrast, peri-inflammatory bone formation is increased in AS, resulting in healing of erosions, ossifying enthesitis, and potential ankylosis of sacroiliac joints and intervertebral connections, and this changes the biomechanical competence of the spine. These changes in bone remodeling and structure contribute to the increased risk of vertebral fractures (in RA and AS) and non-vertebral fractures (in RA), and this risk is related to severity of disease and is independent of and superimposed on background fracture risk. Identifying patients who have RA and AS and are at high fracture risk and considering fracture prevention are, therefore, advocated in guidelines. Local peri-inflammatory bone loss and osteitis occur early and precede and predict erosive bone destruction in RA and AS and syndesmophytes in AS, which can occur despite clinically detectable inflammation (the so-called ‘disconnection’). With the availability of new techniques to evaluate peri-inflammatory bone loss, osteitis, and erosions, peri-inflammatory bone changes are an exciting field for further research in the context of osteoimmunology.

Introduction
The concept of osteoimmunology emerged more than a decade ago and is based on rapidly growing insight into the functional interdependence between the immune system and bone at the anatomical, vascular, cellular, and molecular levels [1]. In 1997, the receptor activator of the nuclear factor-kappa-B ligand (RANKL)/RANK/osteoprotegerin (OPG) pathway was identified as a crucial molecular pathway of the coupling between osteoblasts and osteoclasts [2]. It appeared that not only osteoblasts but also activated T lymphocytes, which play a crucial role in the pathogenesis of rheumatoid arthritis (RA), and many other inflammatory cells can produce RANKL, which stimulates the differentiation and activation of osteoclasts [3]. These findings have contributed to the birth of osteoimmunology as a discipline.

Because of the multiple interconnections and interactions of bone and the immune system, bone is a major target of chronic inflammation in RA and ankylosing spondylitis (AS). Inflammation increases bone resorption and results in suppressed local bone formation in RA and locally increased bone formation in AS, causing a wide spectrum of bone involvement in RA and AS [4,5].

Osteoporosis has been defined as a bone mineral density (BMD) of lower than 2.5 standard deviations of healthy young adults and in daily practice is measured by dual-energy x-ray absorptiometry (DXA) at the spine and hip [6]. However, the bone disease component in RA and AS is much more complex, especially around the sites of inflammation. We reviewed the literature on the quantification of local and general bone changes and their relation to the structural damage of bone, disease activity parameters, and fracture risk in the context of osteoimmunology, both in RA and AS. We have chosen to focus on RA and AS since these inflammatory rheumatic diseases have the highest prevalence and since, in both diseases, characteristic but different types of bone involvement may occur.

Anatomical and molecular cross-talk between bone and the immune system
Multiple anatomical and vascular contacts and overlapping and interacting cellular and molecular mechanisms are involved in the regulation of bone turnover and the immune system, so that one can no longer view either
system in isolation but should consider bone and the immune system to be an integrated whole [4,5].

**Anatomical connections**

Bone, by virtue of its anatomy and vascularization, is at the inside and outside and is in direct and indirect and in close and distant contact with the immune system. At the inside, bones are the host for hematopoiesis, allowing bone and immune cells to cooperate locally. At the outside, bone is in direct contact with the periost, the synovial enthesis within the joints at the periost- and cartilage-free bare area [7], the fibrous tendon enthesis, the calcified component of cartilage and tendon insertions, and the intervertebral discs.

Until recently, it was thought, on the basis of plain radiographs of the hands, that there is only rarely a direct anatomical connection between bone marrow and joint space. Bone erosions have been found in hand joints of presumably healthy controls in less than 1% with plain radiology and in 2% with MRI [8]. However, exciting new data have shown that, with the use of high-resolution quantitative computer tomography (HRqCT), small erosions (<1.9 mm) in the metacarpophalangeal (MCP) joints can be found in 37% of healthy subjects without any signs or symptoms of RA, indicating that small erosions are not specific for RA [9]. Large erosions (>1.9 mm) were found to be specific for RA. Interestingly, 58% of erosions detected by HRqCT in healthy volunteers were not visible on plain radiographs [9]. In healthy controls, the erosions in the MCP joints were not randomly located but were located at the bare area and at high-pressure points adjacent to ligaments, which are erosion-prone sites in RA [10]. Bone erosions are also extremely common in healthy controls in the entheses [11] and in the vertebral cortices covered by periost and the intervertebral discs (in AS) [12]. The immune system, bone, and its internal and external surfaces not only are connected by these local anatomical connections but also are connected with the general circulation by the main bone nutrition arteries and locally with the periost (by its vasculature that perforates cortical bone) and within the bone compartment by attachments of fibrous enthesis and the calcified components of cartilage and fibrocartilage up to the tidemark, which separates calcified from non-calcified components of cartilage and tendons [11].

**Molecular connections**

Bone cells exert major effects on the immune system. Bone cells interact with immune cells and play an essential role in the development of the bone marrow space during growth [13] and during fracture healing [14]. Osteoblasts play a central role in the regulation of renewal and differentiation of hematopoietic stem cells (HSCs) and of B cells in niches near the endosteum [15-17]. Metabolic pathways of the osteoblast which are involved in bone remodeling are also involved in the regulation of HSCs by osteoblasts, such as the calcium receptor, parathyroid hormone (PTH), bone morpho-

getic proteins (BMPs), the Wnt signaling, and cell-cell interactions by the NOTCH (Notch homolog, translocation-associated (Drosophila)) signaling pathway [15-19]. On the other hand, multiple cytokines, chemokines, and growth factors of immune cells such as T and B cells, fibroblasts, dendritic cells, and macrophages directly or indirectly regulate osteoblast and osteoclast activity by producing or influencing the production of the RANKL/RANK/OPG pathway, tumor necrosis factor-alpha (TNFα), interferon-gamma (IFNγ), and interleukins (such as IL-1, IL-6, IL-15, IL-17, IL-18, and IL-23) and the Wnt signaling with involvement of Dikkoppf (DKK), sclerostin, and BMP [4,5,19-21].

In RA, bone loss and bone destruction are dependent on the imbalance between osteoclastogenic and anti-

osteoclastogenic factors. T-cell infiltration in the synovium is a hallmark of RA. TH17 cells, whose induction is regulated by dendritic cells that produce transforming growth factor-beta, IL-6, and IL-23, secrete IL-17, which induces RANKL in fibroblasts and activates synovial macrophages to secrete TNFα, IL-1, and IL-6, which directly or indirectly activate osteoclastogenesis [1]. Other direct or indirect osteoclastogenic factors include monocyte/macrophage colony-stimulating factor, IL-11, IL-15, oncostatin M, leukemia inhibitor factor, and prostaglandins of the E series (PGE) [22-24]. Inhibitors of osteoclastogenesis in RA include TH1 (producing IFNγ) and TH2 (producing IL-4) cells and possibly T helper regulatory (THREG) cells [1].

In AS, increased bone formation, as reflected by syndesmophyte formation in the spine, is related to decreased serum levels of DKK [25] and sclerostin [21], both inhibitors of bone formation, and to serum levels of BMP, which is essential for enchondral bone formation [26], and of CTX-II [27], which reflects cartilage destruction that occurs during enchondral bone formation in syndesmophytes [26-28]. There is, thus, increasing evidence that immune cells and cytokines are critically responsible for the changes in bone resorption and formation and vice versa, resulting in changes in bone quality in chronic inflammatory conditions. These conditions include RA, spondylarthopathies (SpAs) (AS, psoriatic arthritis, and inflammatory bowel disease), systemic lupus erythematosus, juvenile RA, periodontal diseases, and even postmenopausal osteoporosis [29]. We reviewed the literature on the quantification of bone involvement in RA and AS. For an in-depth discussion of the underlying metabolic pathways, a topic that is beyond
the scope of this review, the reader is referred to other reviews [4,5].

**Histology of bone in rheumatoid arthritis and ankylosing spondylitis**

**Bone resorption**

Bone resorption is increased in RA and AS. In RA, this has been demonstrated histologically by the presence of activated osteoclasts in the pannus at the site of bone erosions [30,31], in the periarticular trabecular and cortical bone [32,33], and, in a general way, in sites distant from inflammation [34]. In AS, osteoclastic bone resorption has been demonstrated in the sacroiliac joints [35-37].

The introduction of MRI has shed new light on the involvement of subchondral bone and bone marrow in RA and AS (Figure 1). Periarticular MRI lesions have been described technically as bone edema (on short T1 inversion recovery (STIR), indicating that fatty bone marrow is replaced by fluid) and osteitis (on T1 after IV gadolinium) [38] and histologically as osteitis as inflammation has been demonstrated on histological examination of these lesions [33]. In joint specimens of patients with RA and with MRI signs of bone edema, histological correlates have been studied in specimens obtained at the time of joint replacement and have shown the presence of greater numbers of osteoclasts than in controls and in patients with osteoarthritis and the presence of T cells, B-cell follicles, plasma cells, macrophages, decreased trabecular bone density, and increased RANKL expression [33].

Osteitis is also a major component of AS [39-42]. Osteitis was described by histology of the vertebrae in 1956 [43] and occurs early in the disease and predicts the occurrence of bone erosions [39]. It has been shown that, as in RA, these lesions contain activated immune cells and osteoclasts [44,45]. In contrast to RA, these lesions differ in their location: in the vertebrae, the entheses, the periost of vertebrae and around the joints, the discovertebral connections, the intervertebral joints and the sacroiliac joints, and, to a lesser degree, the peripheral joints, mainly hips and shoulders (Figure 1) [46,47].

**Bone formation**

In spite of the presence of cells with early markers of osteoblasts in and around erosions in RA, bone formation is locally suppressed [48]. This uncoupling of bone resorption and bone formation contributes to the only rare occurrence of healing bone erosions [49] and results in persisting direct local connections between the joint cavity and subchondral bone and thus between synovitis and osteitis. In contrast, in AS, local peri-inflammatory bone formation is increased, resulting in healing of erosions, ossifying enthesitis, and potential ankylosis of sacroiliac joints and of intervertebral connections. The ossification of entheses and sacroiliac joints involves calcification of the fibrocartilage, followed by enchondral bone formation; that is, calcified cartilage is replaced by bone through osteoclastic resorption of calcified cartilage and deposition of bone layers on the inside of the resorption cavity with a very slow evolution and with prolonged periods of arrest [50].

**Bone biomarkers**

In patients with RA, markers of bone resorption are increased in comparison with controls [51]. Correlations between bone markers, bone erosions, and bone loss in RA varied according to study designs (cross-sectional or longitudinal), patient selection, and study endpoints (disease activity score, radiology, and MRI) [52]. Baseline markers of bone and cartilage breakdown (CTX-I and CTX-II) and the RANKL/OPG ratio were related to
short- and long-term (up to 11 years for RANKL/OPG) progression of joint damage in RA, independently of other risk factors of bone erosions [53,54]. Increased markers of bone resorption were related to increased fracture risk [49]. Studies on markers of bone formation in RA, such as osteocalcin, are scarce and show contradictory results, except low serum values in glucocorticoid (GC) users [55,56].

In AS, markers of bone resorption were increased [27,57] and were related to inflammation as measured by serum IL-6 [58]. Increased serum levels of RANKL have been reported [59] with decreased OPG [60,61], and RANKL expression is increased in peripheral arthritis of SpA [62]. Markers of bone formation (type I collagen N-terminal propeptide, or PINP) were related to age, disease duration, and markers of bone resorption (CTX-I) but not with low BMD in the hip or spine [63]. Markers of cartilage breakdown (CTX-II) were related to progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and the appearance of syndesmophytes [27].

**Imaging of bone in rheumatoid arthritis and ankylosing spondylitis**

Many methods, including histomorphometry, imaging (Figure 2), and biomarkers, have been used to study the effect of inflammation on structural and functional aspects of bone in RA and AS. Conventional radiology of the peripheral joints and the spine is used for identifying erosions, joint space narrowing, enthesitis, and syndesmophytes for diagnosis; assessment of disease progression; and standardized scoring in clinical trials, but it is estimated that bone loss of less than 20% to 40% cannot be detected on plain radiographs [64].

Methods that quantify changes in periarticular bone include radiogrammetry, digitalized radiogrammetry (DXR) [65], peripheral dual-energy x-ray absorptiometry (pDXA) [66], quantitative ultrasound (QUS) [67], high-resolution digital radiography [68], high-resolution peripheral qCT [9], and MRI [8], and methods that quantify changes in the vertebrae include DXA, qCT, MRI, and morphometry by vertebral fracture assessment on x-rays or DXA images [69] (Figure 2). At other sites of the skeleton, single x-ray absorptiometry, qCT, MRI, DXA, and QUS are available; of these, DXA is considered the gold standard [70]. Semiquantitative scoring of osteitis on MRI in the vertebrae has been standardized [40,42,71]. Local peri-inflammatory bone formation can be evaluated semiquantitatively in a standardized way on radiographs for scoring of syndesmophytes [41,42,72]. These techniques differ in regions of interest that can be measured, in the ability to measure cortical and trabecular bone separately or in combination, and in radiation dose, cost, and precision [64,73] (Table 1).

**Periarticular bone loss and osteitis in rheumatoid arthritis**

On plain radiographs of the hands, periarticular trabecular bone loss results in diffuse or spotty demineralization and blurred or glassy bone and cortical bone loss in tunneling, lamellation, or striation of cortical bone [74] (Figure 3). Quantification of bone in the hands has consistently shown that patients with RA have lower BMD than controls and lose bone during follow-up, depending on treatment (see below) [75-77]. Cortical bone loss occurs early in the disease, preferentially around affected joints and before generalized osteoporosis can be detected [51,78]. In studies using peripheral qCT at the forearm, trabecular bone loss was more prominent than cortical bone loss in RA patients using GCs [79,80].

Hand bone loss is a sensitive outcome marker for radiological progression. The 1-year hand bone loss measured by DXR predicted the 5- and 10-year occurrence of erosions in RA [73,81] and was a useful predictor of the bone destruction in patients with early unclassified polyarthritis [82]. Hand bone loss measured by DXR correlated with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), disease activity score using 28 joint counts (DAS28), the presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP), health assessment questionnaire (HAQ) score, disease duration, and Sharp score [66,83,84]. In the forearm and calcaneus, trabecular but not cortical periarticular bone loss measured by DXA in early RA correlated with ESR, CRP, RF, and HAQ score [80]. DXR correlated with hip BMD and the presence of morphometric vertebral fractures and non-vertebral fractures in RA [85]. DXR-BMD performed as well as other peripheral BMD measurements for prediction of wrist, hip, and vertebral fractures in the Study of Osteoporotic Fractures [86].

Periarticular osteitis is a frequent finding in RA (45% to 64% of patients with RA) and has remarkable similarities with periarticular bone loss in RA (Figure 1) [87]. Osteitis is found early in the disease process, is predictive of radiographic damage, including erosions and joint space narrowing, SF-36 (short-form 36-question health survey) score function, and tendon function, and is related to clinical parameters CRP and IL-6 in early RA and to painful and aggressive disease [87-94]. Scoring of MRI edema has been standardized by OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) [88]. Osteitis is characterized by trabecular bone loss on histology [66,84-96], but no studies on the relation between osteitis and quantification of bone loss were found.

**Generalized bone loss in rheumatoid arthritis**

BMD is a major determinant of the risk of fractures, but the relationship between BMD and fracture risk is less
clear in RA than in postmenopausal osteoporosis, indicating that factors other than those captured by measuring BMD are involved in the pathophysiology of fractures in RA.

Patients with RA have a decreased BMD in the spine and hip and consequently have a higher prevalence of osteoporosis [56,97-101]. However, this was not confirmed in the Canadian Multicentre Osteoporosis Study (CaMos) [102]. In early untreated RA, BMD was related to longer symptom duration, the presence of RF [103] and anti-CCP [104], disease activity score [105], and the presence and progression of joint damage [106].

The interpretation of longitudinal changes in RA is complicated by the lack of untreated patients, and this limits our insights into the natural evolution of bone changes in RA to the above-mentioned studies. In one study with early untreated RA, bone loss was found in the spine and trochanter for a period of one year [107]. However, Kroot and colleagues [108] did not find bone loss over the course of a 10-year follow-up in RA patients treated with disease-modifying antirheumatic drugs, except when these patients were treated with GCs. Generalized bone loss was related to joint damage in some studies [109,110], but this relation disappeared after multivariate adjustment [111]. No correlation between BMD and the presence of vertebral fractures in RA patients treated with GCs was found [112].

Fracture risk in rheumatoid arthritis
In the largest epidemiological study, patients with RA were at increased risk for fractures of osteoporotic fractures (relative risk (RR) 1.5), fractures of the hip (RR 2.0), clinical vertebral fractures (RR 2.4), and fractures of the pelvis (RR 2.2) [113]. The risk of morphometric vertebral fractures was also increased [114,115]. In some but not all studies, the risk of fractures of the humerus (RR 1.9), wrist (RR 1.2), and tibia/fibula (RR 1.3) was increased [75,116,117].

The etiology of increased fracture risk in RA is multifactorial and superimposed on and independent of
BMD and other clinical risk factors for fractures, including the use of GCs. RA is included as an independent clinical risk factor for 10-year fracture risk calculation for major and hip fractures in the fracture risk assessment tool (FRAX) case-finding algorithm [118]. Stress fractures have been found in 0.8% of patients with RA, can be difficult to diagnose, and were related to GC use but not to BMD [119].

Fracture risk in RA was related to the duration of RA [120], the severity of disease, and its musculoskeletal consequences, such as disability, HAQ score, lack of physical activity, and impaired grip strength [120-122]. Vertebral fractures were related to disease duration and severity [69]. In the general population, fracture risk was related to serum levels of IL-6, TNF, and CRP [123] and parameters of bone resorption [124], all of which can be increased in RA. Extraskeletal risk factors that influence fracture risk include increased risk of fall rates which were related to number of swollen joints and impaired balance tests [125].

**Risk predictors of bone changes in rheumatoid arthritis**

Currently, the most widely used case-finding algorithm for calculating the 10-year fracture risk for major and hip fractures is the FRAX tool [118]. FRAX includes RA as a risk for fractures, independently of and superimposed on other risk factors, including BMD and use of GCs [118]. No fracture risk calculator that also includes other risk factors that are related to RA, such as disease duration and disease severity, is available. The Garvan fracture risk calculator (GFRC) can be used to calculate the 5- and 10-year fracture risk which includes the number of recent falls and the number of previous fractures but lacks RA as a risk factor [126]. Fracture risk is higher with GFRC than with FRAX in patients with recent falls [126]. In view of the increased fracture risk in patients with RA, systematic evaluation of fracture risk should be considered using FRAX, disease severity, and duration, and GFRC is helpful when patients report recent falls. Risk of low BMD is difficult to estimate in RA [90], and this suggests that bone densitometry should also be considered in fracture risk calculation in patients with active RA [127]. Many risk factors, including baseline disease severity, RF, anti-CCP, baseline bone destruction, the RANKL/OPG ratio, and CTX-I and CTX-II, have been identified for the prediction of bone erosions in RA. This pallet of predictors can now be extended with measurement of changes in periarticular bone (by DXR) and osteitis (on MRI) early in the disease [73,81,82]. Additional studies will be necessary to study the relation between osteitis and bone loss.

### Table 1. Techniques to assess hand bone damage in rheumatoid arthritis

| Studied features | Advantages | Disadvantages |
|------------------|------------|---------------|
| **CR** | Bone erosion | Gold standard | Low sensibility |
| Joint space narrowing | Easy accessibility | No evaluation of bone density |
| | Low cost | Ionizing radiation |
| MRI | Bone erosion | Early detection of bone erosions | Expensive |
| Bone edema | Prediction of erosive progression | Uncomfortable |
| Synovitis | Monitoring bone change | No evaluation of bone density |
| Tenosynovitis | Measurement of erosion volume | |
| Bone density | Absence of radiation exposure | |
| **CT** | Bone erosion | High resolution | No evaluation of bone density, synovitis, and bone edema |
| | | | Ionizing radiation |
| **US** | Bone erosion | Non-invasiveness | No evaluation of bone edema |
| | Easy accessibility | Sensibility depending on joint accessibility |
| Synovitis | | |
| Tenosynovitis | Low cost | |
| Bone density | Monitoring bone change | Operator-dependent |
| | Investigating cortical and trabecular bone separately | |
| | Absence of radiation exposure | |
| **DXA** | Bone density | Early detection of bone damage | No evaluation of bone erosion, bone edema, and synovitis |
| | Small effective radiation dose | |
| **DXR** | Bone density | Better reproducibility than DXA | No evaluation of bone erosion, bone edema, and synovitis |
| | Higher sensitivity than DXA | |
| | Predictive of erosive disease | |
| | | Ionizing radiation |

CR, computed radiography; CT, computed tomography; DXA, dual-energy x-ray absorptiometry; DXR, digital radiogrammetry; MRI, magnetic resonance imaging; US, ultrasound. Reprinted with permission from Elsevier [73].

Geusens and Lems Arthritis Research & Therapy 2011, 13:242 http://arthritis-research.com/content/13/5/242
Effect of treatment on bone changes in rheumatoid arthritis

As the pathophysiology of bone loss in RA is taken into account (Figure 4), therapy should be directed at suppressing inflammation and bone resorption and restoring bone formation. No randomized placebo-controlled trials (RCTs) on the effect of treatment on fracture risk in RA are available. However, the available data suggest that control of inflammation (TNF blockade and appropriate dose of GCs), specific inhibition of bone resorption (bisphosphonates and denosumab), strontium ranelate, and restoration of the balance between bone resorption and formation (teriparatide and PTH) are candidates for such studies. Bone loss early in the disease continued despite clinical improvement and sufficient control of inflammation through treatment, indicating a disconnect between clinical inflammation and intramedullary bone loss [128]. However, these studies did not include TNF blockers, and, at that time, remission was not a realistic tool of therapy. Suppression of inflammation with TNF blockers such as infliximab and adalimumab decreased markers of bone resorption and the RANKL/OPG ratio [129], decreased osteitis, and reduced or arrested generalized (in spine and hip) bone loss [75]. Infliximab, however, did not arrest periarticular bone loss [129]. In the Behandelstrategieën voor Reumatoide Artritis (BEST) study, both bone loss at the metacarpals and radiographic joint damage were lower in patients adequately treated with combination therapy of methotrexate plus high-dose prednisone or infliximab than in patients with suboptimal treatment [130].

Several pilot studies on the effect of antiresorptive drugs on bone in RA have been performed. Pamidronate reduced bone turnover in RA [131]. Zoledronate decreased the number of hand and wrist bones with erosions [132]. Denosumab strongly suppressed bone turnover and, in higher dosages than advocated for the treatment of postmenopausal osteoporotic women, prevented the occurrence of new erosions and increased BMD in the spine, hip, and hand, without an effect on joint space narrowing and without suppressing inflammation, indicating an effect on bone metabolism but not on cartilage metabolism [133-136].

The effects of GCs on bone loss and fracture risk in RA should be interpreted with caution as GCs have a dual effect on bone in RA. On the one hand, controlling inflammation with GCs strongly reduces bone loss, whereas, on the other hand, GCs enhance bone resorption, suppress bone formation, and induce osteocyte apoptosis.

Studies in glucocorticoid-induced osteoporosis (GIOP) included patients with RA. None of these studies had fracture prevention as a primary endpoint, and no data on the GIOP studies on fracture prevention in RA separately are available (see [137] for a recent review). RCTs in GIOP showed that bisphosphonate treatment (alendronate, risedronate, and zoledronate) and teriparatide prevented bone loss and increased BMD. Alendronate and risedronate decreased the risk of vertebral fractures versus placebo and teriparatide versus alendronate. No convincing evidence on fracture risk in GIOP for calcium and vitamin D supplements (calcitriol or alfacalcidol) is available. However, most RCTs in GIOP provided calcium and vitamin D supplements. Most guidelines, therefore, advocate calcium and vitamin D supplements, bisphosphonates, and eventually teriparatide as a second choice because of its higher cost price in the prevention of GIOP in patients at high risk, such as those with persistent disease activity, high dose of GCs, or high background risk such as menopause, age, low BMD, and the presence of clinical risk factors [138,139].

Taken together, these data indicate that control of inflammation is able to halt bone loss and suppress osteitis in RA. Bisphosphonates are the front-line choice for fracture prevention in GIOP, but in patients with a very high fracture risk, teriparatide might be an attractive alternative. The effect of denosumab indicates that osteoclasts are the final pathway in bone erosions and local and generalized bone loss and that the bone destruction component of RA can be disconnected from inflammation by targeting RANKL.
Generalized bone loss in ankylosing spondylitis

Bone loss in the vertebrae occurs early in the disease, as shown by DXA [140] and qCT [141]. In advanced disease, the occurrence of syndesmophytes and periosteal and discal bone apposition does not allow intravertebral bone changes with DXA to be measured accurately. Combined analyses of DXA and QCT in patients with early and long-standing disease indicate that bone loss in the vertebrae occurs early in the disease and can be measured by DXA and QCT but that, in long-standing disease, DXA of the spine can be normal, in spite of further intravertebral bone loss as shown with qCT [142,143]. As a result, in early disease, osteoporosis was found more frequently in the spine than in the hip, whereas in patients with long-standing disease, osteoporosis was more frequent in the hip [75]. Hip BMD was related to the presence of syndesmophytes and vertebral fractures, to disease duration and activity [142,144], and to CRP [145]. Osteitis in the vertebrae precedes the development of erosions and syndesmophytes [41,42].

Fracture risk in ankylosing spondylitis

Morphometric vertebral fractures (with a deformation of 15% or 20%) have been reported to be 10% to 30% in groups of patients with AS [146]. The odds ratios of clinical vertebral fractures were 7.7 in a retrospective population-based study [147] and 3.3 in a primary care-based nested case control study [148]. In both studies, the risk of non-vertebral fractures was not increased.

The risk of vertebral fractures is multifactorial and independent of and superimposed on other clinical risk factors [118].

Vertebral fracture risk in AS was higher in men than in women and was associated with low BMD, disease activity, and the extent of syndesmophytes [144,149]. Vertebral fractures contributed to irreversible hyperkyphosis, which is characteristic in some patients with advanced disease with extensive syndesmophytes (bamboo spine) [150,151].

Apart from presenting with these ‘classical’ vertebral fractures, patients with AS can present with vertebral fractures that are specifically reported in AS. First, erosions at the anterior corners and at the endplates of vertebrae (Andersson and Romanus lesions) result in vertebral deformities if erosions are extensive and the results of such measurements should not be considered a classical vertebral fracture (Figure 5) [75,152]. Second, in a survey of 15,000 patients with AS, 0.4% reported clinical vertebral fractures with major neurological complications [153]. Third, owing to the stiffening of the spine by syndesmophytes, transvertebral fractures have been described [153]. Fourth, fractures can occur in the ossified connections between the vertebrae [153]. In all of these cases, CT, MRI, and eventually bone scintigraphy are helpful to identify these lesions and the extent of neurological consequences (Figure 6) [154].

Risk predictors of bone changes in ankylosing spondylitis

The diagnosis of vertebral fractures is hampered by the finding that only one out of three morphometric vertebral fractures is accompanied by clinical signs and symptoms of an acute fracture. This is probably even less in patients with AS as fractures of the vertebrae and their annexes can be easily overlooked when a flare of back pain is considered to be of inflammatory origin without taking into account the possibility of a fracture. In case of a flare of back pain, special attention, therefore, is necessary to

Figure 4. Effect of inflammation on bone and fracture risk in rheumatoid arthritis.
diagnose vertebral fractures in AS, even after minimal trauma. Additional imaging (CT, MRI, and bone scintigraphy) might be necessary in patients in whom a fracture is suspected in the absence of abnormalities on conventional radiographs. On the basis of the limited data on fracture risk in AS, vertebral fractures especially should be considered in patients with a flare of back pain, persistent inflammation, long disease duration, hyperkyphosis with increased occiput-wall distance, bamboo spine, and persistent pain after trauma, even low-energy trauma. The FRAX algorithm can be used to calculate the 10-year fracture risk but cannot be used to separately calculate the risk of clinical vertebral fractures [118].

Risk factors to predict erosive sacroiliitis have been identified. These include male gender, CRP, B27, clinical symptoms, family history [155-157], and the occurrence of syndesmophytes (such as B27, uveitis, no peripheral arthritis, prevalent syndesmophytes, and disease duration) [72,158,159]. Also, CTX-II has been shown to predict syndesmophytes, which could reflect cartilage destruction during enchondral new bone formation in enthesitis, including syndesmophytes [27]. These risk factors can now be extended with subchondral bone involvement (as defined by osteitis on MRI) that has been shown to predict erosive sacroiliitis [39] and the occurrence of syndesmophytes [160,161]. To predict radiographic erosive sacroiliitis, the Assessment of Spondylo-Arthritis international Society recently developed and validated criteria that included active signs of inflammation on MRI, which are defined as active inflammatory lesions of sacroiliac joints with definite bone marrow edema/osteitis [156,157].

**Effect of treatment on bone changes in ankylosing spondylitis**

As the pathophysiology of vertebral fractures in AS is taken into account (Figure 7), therapy should be directed at suppressing inflammation, bone resorption, and bone formation. No RCTs on the effect of treatment on the risk
of vertebral fractures in AS are available. In the General Practice Research Database, the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a 30% decrease in the risk of clinical vertebral fractures, but this has not been studied prospectively [75,148]. In general, continuous use of NSAIDs, in comparison with intermittent use, and celecoxib decreased the formation of syndesmophytes [148,162]. The mechanisms of these effects are unclear. NSAIDs inhibit bone formation, as shown in fracture healing, which is also an inflammation-driven model of increased bone formation [163,164]. One other explanation is that pain relief can ameliorate function and decrease immobility [75]. Limited studies with bisphosphonates indicated inhibition of inflammation in AS [165]. Zoledronate did not prevent the occurrence of syndesmophytes in rats [166]. Bisphosphonates, however, can be considered in the treatment of osteoporosis in high-risk patients [167]. TNF blockade decreased osteitis, prevented bone loss, and decreased CRP and IL-6 [145,168] but had no effect on the occurrence of syndesmophytes [169]. Taken together, these data indicate that control of inflammation is able to halt bone loss and suppress osteitis in AS but not the occurrence of syndesmophytes. Further research is needed to understand why NSAIDs could decrease fracture risk and syndesmophyte formation, why TNF blockade prevents bone loss but not syndesmophyte formation, and new ways to prevent syndesmophyte formation.

Discussion and summary
These data indicate that bone is a major target for inflammation and that bone loss and osteoporosis are common features that contribute to the increased fracture risk in RA and AS. However, the problem of bone involvement in RA and AS is more complex than in primary osteoporosis alone. The consistent finding of peri-inflammatory bone loss and osteitis in both RA and AS raises questions, besides fracture risk, about the clinical significance of bone loss.

Periarticular bone loss and osteitis coincide early in RA and AS and not only precede but also predict the occurrence of visible erosions [76]. This raises the question of the mechanism by which these anatomical coincident changes in the joints, entheses, and bone marrow occur. As described above, no direct anatomical or vascular connection between the joint cavity and bone marrow is present, but some healthy subjects can have small erosions in the MCP joints without having RA and have erosions at the entheses and vertebral cortices. In subjects with small erosions before RA or AS becomes apparent clinically, it can be assumed that, when they develop arthritis or enthesitis, the erosions allow immediate contact with bone marrow, resulting in coincident joint, enthesis, and bone marrow inflammation. Healthy subjects without such erosions could develop small erosions, resulting in measurable peri-inflammatory bone loss, before they can be identified on radiographs or MRI because of the spatial resolution of radiology and MRI and the single-plane images of radiographs. Another hypothesis is that RA and AS are primarily bone marrow diseases [170,171], with secondary invasion of the joint via erosions created by intramedullary activated osteoclasts or via pre-existing erosions. Indeed, CD34+ bone marrow stem cells have been shown to be abnormally
sensitive to TNFα to produce fibroblast-like cells [172],
suggesting an underlying bone marrow stem cell
abnormality in RA.

In AS, the finding of early osteitis is even more
intriguing as osteitis is occurring in the vertebrae, where
no synovium but periost is present at the anterior sites
and discs between vertebrae. Local communication with
the periost is possible by the local vascular connections
or pre-existing erosions, leaving open the possibility that
periost is the primary location of inflammation in AS.
The same applies for the intervertebral disc, which has no
direct vascular contact but can have pre-existing ero-
sions. Whether RA and AS are initialized in the joints,
enthesis, or the bone marrow is a growing field of debate
[170], and such hypotheses will need much more study.

Regardless of these anatomical considerations, when
the size of bone edema that can be found by MRI and the
extent of early periarticular bone loss are taken into
account, it seems that inflammation is as intense and
extensive inside bone marrow as in the synovial joint in
RA and AS and in the enthesis in AS. As bone loss and
bone edema occur early in the disease, these findings
indicate that bone marrow inflammation – and not just
joint or enthesis inflammation – is a classical feature of
early RA and AS. To what degree impaired osteoblast
function is associated with loss of control of HSC and B-
cell differentiation in their subendosteal niches in RA is
unknown and needs further study as B-cell proliferation
is seen in RA but not of AS [173-175].

The finding that bone involvement can be disconnected
from clinically detectable inflammation is quite intrigu-
ing. In RA, bone erosions can progress even when the
inflammatory process is adequately controlled (that is, in
clinical remission) [176], and progress of bone erosions
can be halted by denosumab in spite of persistent inflam-
ination [133-136]. In AS, the occurrence of syndesmes-
phyes can progress in spite of suppression of inflam-
mation by TNF blockade [160]. These findings have been
described as a disconnection between inflammation and
bone destruction and repair.

The correlation and eventual disconnection between
osteitis and bone loss, parameters of disease activity,
and erosions suggest a dual time-dependent role for the
occurrence of erosions. Early in the disease process, the
primary negative effect of pre-existing or newly formed
erosions is the connection they create between the bone
marrow and the joints, periost, and entheses. In this way,
erosions contribute to local amplification of inflammation
by allowing bone marrow cells to have direct local
connection with extraosseous structures and creating a
vicious circle of inflammation between joints, periost,
entheses, and bone marrow [177]. Only in a later stage do
erosions contribute to loss of function [178]. In this
hypothesis, the attack of inflammation on bone by
stimulating osteoclasts has far-reaching consequences.
First, it would indicate that timely disease suppression
and the prevention of the development of a first erosion
rather than halting erosion progression should be
considered a primary objective, both in RA and AS [179].
Second, periarticular bone loss and osteitis should be
considered, at least theoretically, an indication for the
presence of erosions, even when erosions cannot be
visualized on radiographs or MRI, and periarticular bone
loss and osteitis should be considered an indication for
early aggressive therapy [180]. Of course, the effectiveness
of antirheumatic treatment based on osteitis should be
demonstrated. Third, the finding of disconnection
between inflammation and bone involvement indicates
that, even when inflammation is clinically under control,
the degree to which bone-directed therapy is indicated
should be studied in order to prevent (further) progres-
sion of erosions and syndesmophytes. In conclusion,
the involvement of bone as a major target of inflammation
in RA and AS raises many questions [10,181-184], opening
perspectives for further research in the understanding
and treatment of the complex bone disease component
of RA and AS.

Abbreviations
anti-CCP, anti-cyclic citrullinated peptide antibody; AS, ankylosing
spondylitis; BMI, bone mineral density; BMP, bone morphogenetic protein;
CRP, C-reactive protein; CT, computed tomography; DKK, Dikkoppf; DXA,
dual-energy x-ray absorptiometry; DXR, digitalized radiogrammetry; ESR,
erythrocyte sedimentation rate; FRAX, fracture risk assessment tool; GC,
glucocorticoid; GFR, Gavarn fracture risk calculator; GIOP, glucocorticoid-
induced osteoporosis; HAQ, health assessment questionnaire; HRqCT, high-
resolution quantitative computer tomography; HSC, hematopoietic stem
cell; IFNγ, interferon-gamma; IL, interleukin; MCP, metacarpophalangeal; MRI,
magnetic resonance imaging; NSAID, non-steroidal anti-inflammatory drug;
OPG, osteoprotegerin; PTH, parathyroid hormone; qCT, quantitative computer
tomography; QUS, quantitative ultrasound; RA, rheumatoid arthritis; RANK,
receptor activator of the nuclear factor-kappa-B; RANKL, receptor activator of
the nuclear factor-kappa-B ligand, RCT, randomized placebo-controlled trial;
RF, rheumatoid factor; RR, relative risk; SpA, spondylarthropathy; TNF, tumor
necrosis factor.

Competing interests
WFL has received speaking fees form Amgen, Eli Lilly, Merck, and Procter and
Gamble.

Author details
1Department of Internal Medicine, Subdivision of Rheumatology, Maastricht
University Medical Center, P. Debyelaan 25 Postbus 5800, 6202 AZ Maastricht,
The Netherlands. 2Biomedical Research Institute, University of Hasselt, Belgium.
3Department of Rheumatology, 3A61 VU Medical Center, Postbox 7057, 1007
MB Amsterdam, The Netherlands.

Published: 30 September 2011

References
1. Takayanagi H. Osteoimmunology and the effects of the immune system on
bone. Nat Rev Rheumatol 2009, 5:567-576.
predicts hip, wrist and vertebral fracture risk in elderly women: a prospective analysis from the study of osteoporotic fractures. Osteoporos Int 2002, 13:588-365.

87. McQueen FM, Dalbeth N: Predicting joint damage in rheumatoid arthritis using MRI scanning. Arthritis Res Ther 2009, 11:24.

88. Bayesens P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseg S, Kven TK: MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011, 70:428-433.

89. McQueen FM, Stewar N, Crabbie D, Crabbie J, Robinson E, Yeoman S, Tan PL, McLean L: Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998, 87:150-156.

90. McQueen FM, Benton N, Perry D, Crabbie J, Robinson E, Yeoman S, McLean L, Stewar N: Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:1814-1823.

91. Hodgson RJ, O'Connor P, Moores R: MRI of rheumatoid arthritis image quantification for the assessment of disease activity, progression and response to therapy. Rheumatology (Oxford) 2008, 47:13-21.

92. Bird P, Conaghan P, Ejbjerg B, McQueen F, Lassere M, Petercy C, Edmonds J, Shnier R, O'Connor P, Haavardsholm E, Emery P, Guenot H, Ostergaard M: The development of the EULAR-OMERACT rheumatoid arthritis MRI reference images atlas. Ann Rheum Dis 2005, 64 Suppl 1:8-10.

93. Tamai M, Kawakami A, Uetani M, Takao S, Arita K, Iwamaoto N, Fujikawa K, Aramaki T, Kawashiri SY, Ishioka K, Kamachi M, Nakamura H, Otsuji T, Ida H, Aoyagi K, Echigo K: A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum 2009, 61:732-776.

94. Herland ML, Ejbjerg B, Harslev-Petersen K, Jacobsen S, Westergaard A, Junk AG, Westergaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjødt P, Pedersen JK, Maggaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallø J, Torfing J, Naarstedt E, Thomsen HS, Ostergaard M, CIMESTRA study group: MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009, 68:384-390.

95. McQueen FM, Gao A, Ostergaard M, King A, Shalley G, Robinson E, Doyle A, Clark B, Dalbeth N: High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 2007, 66:1581-1587.

96. Dalbeth N, Smith T, Gray S, Doyle A, Antill P, Lobo M, Robinson E, King A, Cornish J, Shalley G, Gao A, McQueen FM: Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis: implications for pathogenesis of erosive disease. Ann Rheum Dis 2009, 68:279-282.

97. Oelzner P, Keller C, Svensson B, Haartström J, BArFOT Study Group: Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol 2003, 30:2590-2596.

98. Gough AK, Lilley J, Eyer S, Holder RL, Emery P: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.

99. Krook EJ, Nieuwenhuizen MG, de Waal Malefijt MC, van Rei PL, Pasker-de Jong PC, Laan RF: Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 2001, 44:1254-1260.

100. Lodder MC, Haugeberg G, Lemi WF, Uhlig T, Orstavik RE, Kostense PJ, Dijkmans BA, Kven TK, Woof AD, Oslo-Turho-Amsterdam (OSTRA) Collaborative Study: Radiographic and magnetic resonance imaging bone oedema in rheumatoid arthritis; the Oslo-Turho-Amsterdam (OSTRA) collaborative study. Arthritis Rheum 2003, 49:209-215.

101. Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Saal K, Voskuyl AE, Hazes JM, Dijkmans BA, Lemi WF: Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004, 63:576-580.

102. Solomon DH, Finkelstein JS, Shadick N, Leboff MS, Winalski CS, Stedman M, Glass R, Brookhart MA, Weinblatt ME, Gravallese EM: The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 2009, 60:1624-1631.

103. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R: Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995, 54:801-806.

104. van Staar TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C: Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3104-3112.

105. Vis M, Haavardsholm EA, Baysens P, Haugeberg G, Uhlig T, Hoff M, Wooff A, Dijkmans BA, Lemi WF, Kven TK: High incidence of vertebral and non-vertebral fractures in the Ostra cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int 2011 Jan 13. [Epub ahead of print].

106. Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C: Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int 2011 Feb 25. [Epub ahead of print].

107. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH: Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis: Arthritis Res Ther 2010, 12:R154.

108. Sinigaglia L, Varenna M, Girasole G, Bianchi G: The risk of fracture in patients with rheumatoid arthritis: a series and case-control study. Ann Rheum Dis 2011, 70:1666-1669.

109. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH: Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 2009, 15:155-160.

110. Haugeberg G, Orstavik RE, Uhlig T, Falch JA, Halje J, Kven TK: Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid
more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005, 32:1290-1298.

134. Lange U, Kluge A, Stunk J, Teichmann J, Bachmann G. Ankylosing spondylitis and bone mineral density—what is the ideal tool for measurement? Rheumatol Int 2003, 26:115-120.

135. Ghoshal I, Ghazi M, Nourjai A, Mounach A, Rezy A, Achemlal I, Reza A, Beja A, El Maghraoui A. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009, 44:772-776.

136. Maillieret JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001, 12:605-609.

137. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 2004, 71:291-295.

138. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994, 21:1877-1882.

139. Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP. Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009, 68:1839-1842.

140. Vosse D, van der Heijde D, Landewe R, Geusens P, Meliaets H, Dougados M, van der Linden S. Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:770-774.

141. Geusens P, Vosse D, van der Heijde D, van Hoof J, van Tubergen A, Raus J, van der Linden S. High prevalence of thoracic vertebral deformities and disc wedging in ankylosing spondylitis patients with hyperkyphosis. J Rheumatol 2001, 28:1836-1861.

142. Montala N, Juanola X, Collantes E, Muñoz-Gomariz E, Gonzalez C, Gratacos J, Zarco P, Sueno JL, Mulero J, Torre-Alonso JC, Balle E, Carmona L. Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 2011, 38:899-907.

143. Geusens P. Comparing morphometric M-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford) 2007, 46:1667-1671.

144. Vosse D, Feldtkeller E, Erlandsen J, Geusens P, van der Linden S. Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol 2004, 31:1983-1985.

145. Wang YF, Teng MM, Chang CY, Wu HT, Wang ST. Imaging manifestations of spinal fractures in ankylosing spondylitis. AJNR Am J Neuroradiol 2005, 26:2067-2076.

146. Rudwaleit M, Habel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The early disease stage in axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009, 61:717-727.

147. Rudwaleit M, Landewe R, van der Heijde D, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowycz WP, Meliaets H, Ollivier I, Sturrock R, van Dijk M, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): classification of patient data by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009, 68:770-776.

148. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akcoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowycz WP, Meliaets H, Sørensen IJ, Ozgocmen S, Roussiou E, Valle-Oñate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.

149. Atagunpudžia, Aytin SZ, Bahadir C, Erer B, Direskeneli H. Determinants of early radiographic progression in ankylosing spondylitis. J Rheumatol 2010, 37:2356-2361.

150. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The natural course of radiographic progression in ankylosing spondylitis—evidence for major individual variations in a large proportion of patients. J Rheumatol 2009, 36:997-1002.

151. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008, 10:104.
M. Lambert RG: Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: a relationship between inflammation and new bone formation. Arthritis Rheum 2009, 60:93-102.

162. Wanders A, Heijde D, Landewe R, Béhier JM, Cailin A, Olivier I, Zeidler H, Dougados M: Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52:1756-1765.

163. Dodwell ER, Latorre JG, Parisini E, Zwettler E, Chandra D, Mulpuri K, Snyder B: NSAID exposure and risk of nonunion: a meta-analysis of case-control and cohort studies. Calcif Tissue Int 2010, 87:193-202.

164. Simon AM, O'Connor JP: Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 2007, 89:500-511.

165. Maksymowych WP, Jiangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766-773.

166. Lories RJ, Derese I, Luyten FP: Induction of fibroblast-like cells from CD34(+) progenitor cells of bone marrow in inflammatory arthritis. J Bone Miner Res 1999, 58:727-730.

167. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Heijde M, Lambert RG: Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis Rheum 2005, 52:3448-3459.

168. Schett G, Caporali R, Manzo A, Vitoio B, Pitazlis C, Montecucco C: Inflammation and new bone formation. Arthritis Rheum 2006, 54:3119-3125.

169. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, Van Zeiden D, Vos K, Breedveld FC, Hazes JM: Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002, 47:383-390.

170. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D: EULAR recommendations for the management of ankylosing spondylitis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.

171. Mundtweiler ML, Maranian P, Brown DH, Silverman JM, Wallace D, Khamma D, Louie J, Furst DE, Weismann MH: The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthritis Res Ther 2009, 11:304.

172. Geusens PP, Leiris WF: Measuring metacarpal cortical bone by digital x-ray radiomometry: a step forward? Arthritis Res Ther 2009, 11:27.

173. McGonagle D: The history of erosions in rheumatoid arthritis: are erosions history? Arthritis Rheum 2010, 62:312-315.

174. van der Heijde D, Rudwaleit M, Sieper J: Justification for including MRI as a tool in the diagnosis of axial SpA. Nat Rev Rheumatol 2010, 6:670-672.

175. van der Heijde D, Rudwaleit M, Landewe RB, Sieper J: Issues and limitations. Nat Rev Rheumatol 2010, 6:666-669.

176. Geusens and Lems Arthritis Research & Therapy 2011, 13:242

http://arthritis-research.com/content/13/5/242

doI:10.1186/ar3375

Cite this article as: Geusens P, Leiris WF: Osteoimmunology and osteoporosis. Arthritis Research & Therapy 2011, 13:242.